Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT02659930
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
- Conditions
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 117
- Registration Number
- NCT02654132
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 114
- Registration Number
- NCT02616640
- Locations
- 🇺🇸
Local Institution - 108, Boston, Massachusetts, United States
🇺🇸Local Institution - 115, Boston, Massachusetts, United States
🇪🇸Local Institution - 504, Madrid, Spain
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT02612779
- Locations
- 🇺🇸
Bay Hematology Oncology, Easton, Maryland, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT02578121
- Locations
- 🇺🇸
University of Arkansas for Medical Science, Little Rock, Arkansas, United States
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 251
- Registration Number
- NCT02576977
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2021-06-15
- Target Recruit Count
- 9
- Registration Number
- NCT02569320
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 150
- Registration Number
- NCT02555839
- Locations
- 🇦🇹
AKH, Universitätsklinik für Innere Medizin I /Klin. Abteilung für Onkologie, Vienna, Austria
🇦🇹LKH Feldkirch, Intern E, Hämatologie, Feldkirch, Austria
🇦🇹SCRI-CCCIT gemeinnützige GmbH & Universitätsklinikum der PMU Salzburg Gemeinnützige Salzburger Landeskliniken BetriebsgmbH, Salzburg, Austria
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 11
- Registration Number
- NCT02548962
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 17
- Registration Number
- NCT02547662
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Sarah Cannon Cancer Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.